Cheng S. Quah

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Paolo Ghia, Andrzej Pluta, Daniel Lysák et al. · Journal of Clinical Oncology · 2020 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

Sandra M. Swain, José Baselga, David Miles et al. · Annals of Oncology · 2014 · 232 citations · Full text

Medicine, Oncology, Pharmacology +17

Fresh Blood and Aged Stored Blood Are Equally Efficacious in Immediately Reversing Anemia-induced Brain Oxygenation Deficits in Humans

Richard B. Weiskopf, John Feiner, Harriet W. Hopf et al. · Anesthesiology · 2006 · 164 citations · Full text

Medicine, Hematology, Neuroscience +15

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles, David Cameron, Igor Bondarenko et al. · European Journal of Cancer · 2016 · 124 citations

Medicine, Oncology, Pharmacology +16

Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia

Kerry A. Rogers, Philip A. Thompson, John N. Allan et al. · Haematologica · 2021 · 108 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13